These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

33 related articles for article (PubMed ID: 19291500)

  • 1. Effect of Memantine in Chronic Poststroke Aphasia: A Clinical Vignette.
    Gawande SR; Joshi AD; Jhaveri RH; Acharya A
    Am J Phys Med Rehabil; 2024 Jun; 103(6):e74-e76. PubMed ID: 38320236
    [No Abstract]   [Full Text] [Related]  

  • 2. Memantine (Namenda) for moderate to severe Alzheimer's disease.
    Ables AZ
    Am Fam Physician; 2004 Mar; 69(6):1491-2. PubMed ID: 15053415
    [No Abstract]   [Full Text] [Related]  

  • 3. Molecule of the month. Memantine hydrochloride.
    Drug News Perspect; 2003; 16(1):55. PubMed ID: 12682671
    [No Abstract]   [Full Text] [Related]  

  • 4. [Little behavior improvement with memantine].
    Potz-Biedermann C
    Med Monatsschr Pharm; 2005 Nov; 28(11):413-4. PubMed ID: 16309030
    [No Abstract]   [Full Text] [Related]  

  • 5. FDA approves memantine drug for treating AD.
    Am J Alzheimers Dis Other Demen; 2003; 18(6):329-30. PubMed ID: 14682078
    [No Abstract]   [Full Text] [Related]  

  • 6. Memantine in the treatment of dementia.
    Maggiore C; Locatelli L; Grandi FC; Pizzolato G;
    Neuroepidemiology; 2007; 28(2):118-9. PubMed ID: 17409774
    [No Abstract]   [Full Text] [Related]  

  • 7. Memantine (Namenda, Forest Pharmaceuticals).
    Roman MW
    Issues Ment Health Nurs; 2009 Mar; 30(3):202. PubMed ID: 19291500
    [No Abstract]   [Full Text] [Related]  

  • 8. Memantine therapy of behavioral symptoms in community-dwelling patients with moderate to severe Alzheimer's disease.
    Grossberg GT; Pejović V; Miller ML; Graham SM
    Dement Geriatr Cogn Disord; 2009; 27(2):164-72. PubMed ID: 19194105
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discontinuing Alzheimer's disease drug therapy: why, when, and how.
    Crutchfield D
    Director; 2008; 16(1):19-21. PubMed ID: 19343870
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Cognitive reserve, cognitive impairment and possibilities of their pharmacological correction].
    Kamchatnov PR
    Zh Nevrol Psikhiatr Im S S Korsakova; 2014; 114(3):87-91. PubMed ID: 24795927
    [No Abstract]   [Full Text] [Related]  

  • 11. Neuroprotection: extrapolating from neurologic diseases to the eye.
    Danesh-Meyer HV; Levin LA
    Am J Ophthalmol; 2009 Aug; 148(2):186-191.e2. PubMed ID: 19464671
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [From symptomatic to disease modifying therapy? Recent developments in the pharmacotherapy of Alzheimer's disease].
    Franke AG; Lieb K; Fellgiebel A
    Fortschr Neurol Psychiatr; 2009 Jun; 77(6):326-33. PubMed ID: 19504422
    [TBL] [Abstract][Full Text] [Related]  

  • 13.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 14.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 15.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 2.